Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Melanie J. Davies; Louise Færch; Ole Kleist Jeppesen; Arash Pakseresht; Sue D. Pedersen; Leigh Perreault; Julio Rosenstock; Iichiro Shimomura; Adie Viljoen; Thomas A. Wadden; Ildiko Lingvay

doi:10.1016/s0140-6736(21)00213-0

Keywords

SemaglutideMedicinePlaceboOverweightType 2 diabetesInternal medicineBody mass indexDiabetes mellitusRandomized controlled trialGlycated hemoglobinPhysical therapyEndocrinologyLiraglutide

Affiliated Institutions

Related Publications

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein , Helen M. Colhoun , Gilles R. Dagenais +97 more

This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 countries. Men and women aged at least 50 years with type 2 diabetes who had eit...

2019 The Lancet 2683 citations

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John Wilding , Rachel L. Batterham , Salvatore Calanna +11 more

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body we...

2021 New England Journal of Medicine 3574 citations

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

A. Michael Lincoff , Kirstine Brown‐Frandsen , Helen M. Colhoun +13 more

In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo i...

2023 New England Journal of Medicine 1860 citations

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( <scp>CANVAS‐R</scp> ): A randomized, placebo‐controlled trial

Bruce Neal , Vlado Perkovic , David R. Matthews +10 more

Aims The primary aim of the CANagliflozin cardioVascular Assessment Study‐Renal (CANVAS‐R) is to determine whether the favourable effects of inhibition of the sodium glucose co‐...

2017 Diabetes Obesity and Metabolism 160 citations

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

Melanie J. Davies , Richard M. Bergenstal , Bruce W. Bode +6 more

clinicaltrials.gov Identifier:NCT01272232.

2015 JAMA 1050 citations

Publication Info

Year: 2021
Type: article
Volume: 397
Issue: 10278
Pages: 971-984
Citations: 1080
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1080

OpenAlex

Cite This

APA Style

                            
                                
                                    Melanie J. Davies, 
                                
                                    Louise Færch, 
                                
                                    Ole Kleist Jeppesen
                                
                                et al.
                            
                            (2021). 
                            Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. 
                            The Lancet
                            , 397
                            (10278)
                            , 971-984.
                            https://doi.org/10.1016/s0140-6736(21)00213-0
                        

Identifiers

DOI: 10.1016/s0140-6736(21)00213-0